NKG2D配体在肿瘤免疫中作用新进展  

New Progress on Tumor-immunology Function of NKG2D Ligands

作　　者：姜孝新[1] 蒋艳[1] 霍治[2] 

机构地区：[1]南华大学附属第一医院,湖南衡阳421000 [2]中南大学基础医学院,湖南长沙410013

出　　处：《肿瘤药学》2012年第1期14-18,共5页Anti-Tumor Pharmacy

基　　金：国家自然基金资助项目(81100663)

摘　　要：NKG2D系自然杀伤性细胞(NK)和CD8+T淋巴细胞表面的激活受体。NKG2D配体分子可被细胞在应急状态和发生感染的情况下诱导表达。在肿瘤免疫监视和肿瘤免疫治疗,进行了大量的研究。NKG2D与其配体分子的结合能够激活NK细胞,并为T细胞提供协同刺激,继而激活机体体液免疫和细胞免疫机制,诱导机体的免疫杀伤作用。活化的NK细胞通过IL-15加强来自供体或受体的抗原递呈细胞(APCs)对T细胞的反应,导致机体对移植物的排斥反应。从另一面来说,经NKG2D受体激活NK细胞后,T调节细胞的数量可减小,这种调节T细胞免疫的能力下降。增加NKG2D与其配体分子的结合,可为寻找新的肿瘤免疫治疗提供研究思路。加强对这方面的研究为提高肿瘤存活期具有重要的临床价值。NKG2D is activation receptors of natural cell killer（NK） and CD8＋T lymphocyte surface.NKG2D ligand molecules could be induced to express when cell is in the emergency state and is infected.In the aspect of tumor immune monitoring and tumor immuno-therapy,it received a lot of research.The combination of NKG2D and its ligand molecules can activate NK cells,and co-excite the T cells,then activate the body＇s immune system and cellular immune mechanism,inducing immune killer role.The activated NK cells strengthen through IL-15 the reaction to T cells of antigen presenting cells（APCs） which are from donors or receptors,causing rejection from the body to graft.From the other side,after NK cells being activated by NKG2D receptor,the number of T cells is reduced,so is the immune ability of regulatory T cells.Increase of the combination of NKG2D and its molecular ligands could provide new ideas in seeking for new immune therapy.So to strengthen the research of this aspect is of important clinic value in improving the survival time of tumor patients.

关 键 词：GM-CSF CTLA-4 MICA NKG2D 

分 类 号：R733[医药卫生—肿瘤]